Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29(11):2200-2207.

Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020;9(6).

Dr. Andrew J. Armstrong

Dr. Tomasz M. Beer

PREVAIL Model for Prostate Cancer Survival

treat

time

hemo

pain

bone

spread

Predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Overall survival in metastatic prostate cancer.

PREVAIL Model for Prostate Cancer

The PREVAIL Model for Prostate Cancer Survival predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

months

Hemoglobin

Albumin

D'Amico Classification

MSKCC/Motzer Criteria for RCC

Manchester Score for Lung Cancer

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function